|
DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,300 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices. |
Tradename: AVODART
Summary for Tradename: AVODART
|
| |||||||||||
Clinical Trials for: AVODARTAVODART® Alopecia Post-marketing Surveillance (PMS) Status: Recruiting Condition: Alopecia Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation Status: Active, not recruiting Condition: Prostate Cancer Bioavailability of Two Combination Products of Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) in Asian Males. Status: Completed Condition: Prostatic Hyperplasia Bioequivalence - Duodart Against Avodart & Omnic Status: Completed Condition: Prostatic Hyperplasia A Study Assessing a Range of Formulations of the Fixed Dose Combination Product Containing Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) to Find a Formulation Which is Bioequivalent to Harnal-D Tablets (Tamsulosin Hydrochloride, 0.2mg) in Healthy Male Subjects From North East Asia Status: Completed Condition: Prostatic Hyperplasia Role of Dutasteride in Patients Undergoing 3D Mapping Biopsy in Early Stage Prostate Cancer Status: Terminated Condition: Prostate Cancer Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride Status: Completed Condition: Hypogonadism; Hypogonadism, Male A Study to Determine the Bioavailability of a Fixed Dose Combination Product of Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) Relative to Co-administration of the Individual Components in Healthy Male Subjects of North East Asian and Non-Asian Ancestry. Status: Completed Condition: Prostatic Hyperplasia ARTS - AVODART After Radical Therapy For Prostate Cancer Study Status: Completed Condition: Neoplasms, Prostate; Prostate Cancer After a Radical Treatment Efficacy and Safety Study of Dutasteride Combined With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptoms (LUTS) Status: Active, not recruiting Condition: BPH Courtesy of ClinicalTrials.org See more clinical trials for this drug | ||||||||||||
Glossary
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist_Flag | Patent Expiration | Exclusivity Expiration | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glaxosmithkline | AVODART | dutasteride | CAPSULE; ORAL | 021319 | Nov 20, 2001 | RX | Yes | 5,565,467 | Y | Y | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Glaxosmithkline | AVODART | dutasteride | CAPSULE; ORAL | 021319 | Nov 20, 2001 | RX | Yes | 5,846,976 | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Glaxosmithkline | AVODART | dutasteride | CAPSULE; ORAL | 021319 | Nov 20, 2001 | RX | Yes | 5,998,427 | Y | Y | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The preview shows a limited data set. Complete access is available with a Subscription | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Paragraph IV activity for: AVODART
| Drugname | Dosage | Strength | RLD | Submissiondate |
| dutasteride | Capsules | 0.5 mg | Avodart | 10/29/2007 |
« Back to Dashboard
DrugPatentWatch Archives
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Connect with Social Media:
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639
`abc